Table 2.
Comparison of test modalities for the detection of asymptomatic malaria
| Subject ID | Age (years) | Gender | Temp (°C) | Hemoglobin (g/dL) | Microscopy (para/µL) | CareStart RDT | Alere Pf Malaria Ag histidine-rich protein 2 rapid diagnostic test | Quantitative reverse transcription polymerase chain reaction (est. para/uL) |
|---|---|---|---|---|---|---|---|---|
| Known CareStart-negative samples | ||||||||
| A-AK-029 | 4 | F | 36.7 | 12.8 | − | − | + | − |
| A-AC-243 | 11 | F | 36.3 | 17.2 | − | − | + | − |
| A-AC-207 | 13 | F | 35.8 | 13 | − | − | − | − |
| A-AK-067 | 14 | M | 37.1 | ND | − | − | ND | − |
| A-AK-031 | 15 | F | 36.2 | 12.6 | − | − | + | − |
| A-AC-210 | 0.25 | F | 36.8 | 11.1 | − | − | − | − |
| A-AK-023 | 7 | M | 36.9 | 13.7 | − | − | − | < 0.02 |
| A-AC-208 | 11 | F | 36.7 | ND | − | − | − | 0.03 |
| A-AC-163 | 9 | M | 36.1 | 12.1 | − | − | + | 0.4 |
| A-AC-194 | 12 | M | 36.4 | ND | − | − | − | 0.5 |
| A-AK-015 | 9 | F | 36.1 | 9.7 | − | − | + | 4 |
| A-AC-239 | 17 | F | 37.0 | 21.4 | − | − | − | 4 |
| A-AC-232 | 15 | F | 36.8 | 15.3 | − | − | − | 8 |
| A-AK-034 | 11 | F | 36.2 | 12.7 | − | − | − | 10 |
| A-AK-026 | 12 | M | 36.5 | 13.6 | − | − | + | 16 |
| A-AK-019 | 16 | F | 35.1 | 13.4 | − | − | + | 23 |
| A-AC-251 | 14 | M | 36.4 | 12.3 | − | − | + | 25 |
| A-AC-245 | 16 | F | 36.1 | 12.2 | − | − | + | 38 |
| A-AK-039 | 12 | M | 36.7 | ND | − | − | + | 39 |
| A-AC-209 | 14 | M | 36.8 | 13.2 | − | − | + | 39 |
| A-AC-229 | 11 | M | 36.7 | 10.5 | − | − | + | 47 |
| A-AC-203 | 14 | F | 36.7 | 12.3 | −− | − | + | 47 |
| A-AK-004 | 8 | F | 37.1 | 12.2 | − | − | − | 66 |
| A-AC-193 | 13 | F | 36.1 | 12.8 | − | − | − | 142 |
| A-AC-228 | 15 | F | 36.4 | 19.6 | + (40) | − | + | 148 |
| Known CareStart-positive samples | ||||||||
| A-AK-035 | 2 | M | 36.7 | 10.4 | − | + | + | − |
| A-AK-070 | 8 | M | 36.5 | 11.8 | − | + | + | − |
| A-AK-036 | 2 | F | 36.9 | 13.6 | − | + | + | 0.08 |
| A-AK-033 | 6 | M | 36.4 | 12.7 | − | + | + | 0.18 |
| A-AK-054 | 13 | M | 36.4 | 11.7 | − | + | − | 0.8 |
| A-AK-001 | 1.5 | F | 36.1 | 10.6 | − | + | + | 1 |
| A-AK-063 | 11 | F | 37.0 | 10.9 | − | + | + | 1 |
| A-AC-221 | 13 | F | 36.4 | 16.6 | + (89) | + | + | 99 |
| A-AK-065 | 2.5 | M | 36.1 | 10.0 | − | + | + | 258 |
| A-AK-058 | 15 | M | 35.7 | 13.7 | − | + | + | 285 |
| A-AK-049 | 11 | M | 36.6 | 12.4 | + (364) | + | + | 301 |
| A-AK-002 | 5 | M | 35.7 | 8.2 | + (584) | + | + | 303 |
| A-AC-192 | 9 | M | 37.7 | 13.2 | + (196) | + | + | 405 |
| A-AK-062 | 8 | M | 36.7 | 14.4 | + (161) | + | + | 455 |
| A-AC-166 | 8 | M | 36.7 | 12.4 | + (380) | + | + | 516 |
| A-AK-011 | 15 | F | 37.4 | 9.9 | + (1,104) | + | + | 527 |
| A-AK-022 | 9 | M | 37.3 | 13.3 | + (1,076) | + | + | 1,023 |
| A-AK-028 | 5 | F | 36.3 | 12.2 | + (724) | + | + | 1,044 |
| A-AK-055 | 4.5 | F | 36.7 | 10.7 | + (6,060) | + | + | 2,204 |
| A-AK-043 | 12 | M | 36.4 | 12.7 | + (1,240) | + | + | 3,136 |
| A-AK-027 | 7 | F | 36.4 | 12.2 | + (2,168) | + | + | 3,527 |
| A-AK-005 | 6 | M | 36.6 | 12.2 | + (2,272) | + | + | 4,556 |
| A-AC-220 | 16 | M | 36.9 | 12.7 | + (2,724) | + | + | 13,215 |
| A-AK-021 | 11 | F | 36.4 | 13.5 | + (11,900) | + | + | 23,623 |
| A-AK-046 | 5 | M | 37.0 | 11.5 | + (18,940) | + | + | 98,177 |
| Overall prevalence | ||||||||
| Prevalence (all 50 samples) | 34% (17/50) | 50% (25/50) | 76% (38/49) | 84% (42/50) | ||||
| Prevalence (CareStart RDT–negative only) | 4% (1/25) | 0% (0/25) | 56% (14/24) | 76% (19/25) | ||||
| Prevalence (CareStart RDT–positive only) | 64% (16/25) | 100% (25/25) | 96% (24/25) | 92% (23/25) | ||||
g/dL = gram per deciliter; µL = microliter; °C = degree Celsius; est. = estimated; ND = not done rapid diagnostic test.